Ameriprise Financial Inc. Acquires 88,542 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Ameriprise Financial Inc. lifted its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 14.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 715,672 shares of the biotechnology company’s stock after acquiring an additional 88,542 shares during the quarter. Ameriprise Financial Inc. owned 0.30% of ADMA Biologics worth $12,274,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Algert Global LLC lifted its holdings in ADMA Biologics by 33.3% during the 4th quarter. Algert Global LLC now owns 272,349 shares of the biotechnology company’s stock valued at $4,671,000 after buying an additional 67,961 shares in the last quarter. Freestone Grove Partners LP purchased a new position in ADMA Biologics during the 4th quarter valued at about $769,000. Northern Trust Corp increased its position in ADMA Biologics by 6.0% during the 4th quarter. Northern Trust Corp now owns 2,575,075 shares of the biotechnology company’s stock valued at $44,163,000 after purchasing an additional 145,387 shares during the period. Oxford Asset Management LLP purchased a new position in ADMA Biologics during the 4th quarter valued at about $230,000. Finally, Oberweis Asset Management Inc. increased its position in ADMA Biologics by 15.0% during the 4th quarter. Oberweis Asset Management Inc. now owns 3,342,560 shares of the biotechnology company’s stock valued at $57,325,000 after purchasing an additional 435,480 shares during the period. Institutional investors own 75.68% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on ADMA. Raymond James raised their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a research report on Thursday, May 8th. StockNews.com lowered shares of ADMA Biologics from a “hold” rating to a “sell” rating in a research note on Friday, May 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.25.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $19.69 on Monday. ADMA Biologics, Inc. has a 12-month low of $9.22 and a 12-month high of $25.67. The stock has a market cap of $4.70 billion, a P/E ratio of 70.32 and a beta of 0.57. The company has a 50-day moving average price of $20.49 and a 200 day moving average price of $18.86. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. During the same quarter in the prior year, the business earned $0.08 earnings per share. ADMA Biologics’s revenue was up 40.2% on a year-over-year basis. Sell-side analysts anticipate that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.